ZAGREB, September 3, 2019 – Dechra Pharmaceuticals, a leading British veterinary medicine producer, stated on Monday that it shifted all the analytical testing methods for products made at its site in Skipton, England, to a new lab in Zagreb, and to its existing Bladel laboratory in the Netherlands, as part of the company’s preparations for “a potential hard Brexit”, Reuters has reported.
This British veterinary firm said that it changed the ownership of all UK marketing authorisations to a new unit in the Netherlands, also within its plans to make itself ready for a Brexit.
“This will allow us to perform batch release within the EU in the likely event that there will be no mutual recognition of quality standards,” Dechra said in a statement.
The Reuters news agency recalls that risks related to Brexit include Britain potentially leaving the EU without a deal.
Dechra did not disclose whether the new measures would impact jobs.
“The company reported a 27% increase in full-year underlying operating profit to 127.4 million pounds (156.41 million dollars) and hiked its full-year dividend by 24% to 31.6 pence,” Reuters reported in the news article headlined “Dechra ramps up contingency plan for a potential hard Brexit”.
In 2015, Dechra Pharmaceuticals bought a 63.3% interest in Croatia’s Genera.
Dechra made that move because it wanted to enter the vaccine market. Genera is the oldest and largest manufacturer of animal health products in Croatia with a strong market share in its local market and neighbouring countries.
It operates three main divisions: Animal Health, which represents the majority of revenue, Agrochemicals and Human Pharmaceuticals.
Over the last few years, vaccines have become a key part of the Animal Health Division. Genera has invested significantly in building its poultry vaccines capabilities, including regulatory submissions in the EU and elsewhere.
More news about Croatia and Brexit can be found in the Politics section.
